Global Human Microbiome Market Analysis and Forecast 2024-2030

Global Human Microbiome Market Analysis and Forecast 2024-2030


Summary

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

According to APO Research, The global Human Microbiome market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Human Microbiome is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Human Microbiome include Vedanta, Seres Therapeutics, Second Genome, Rebiotix, ActoGeniX, Enterome BioScience, AvidBiotics, 4D Pharma Research Ltd and Enterologics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes

This report presents an overview of global market for Human Microbiome, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Human Microbiome, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Microbiome, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Microbiome revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Human Microbiome market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Human Microbiome revenue, projected growth trends, production technology, application and end-user industry.

Human Microbiome segment by Company

Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Human Microbiome segment by Type

Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Human Microbiome segment by Application

Treatment
Diagnosis
Human Microbiome segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Microbiome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Microbiome and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Microbiome.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Human Microbiome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Human Microbiome company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Microbiome revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Human Microbiome Market by Type
1.2.1 Global Human Microbiome Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Gastrointestinal Tract Human Micobiome
1.2.3 Urogenital Tract Human Micobiome
1.2.4 Others
1.3 Human Microbiome Market by Application
1.3.1 Global Human Microbiome Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Treatment
1.3.3 Diagnosis
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Human Microbiome Market Dynamics
2.1 Human Microbiome Industry Trends
2.2 Human Microbiome Industry Drivers
2.3 Human Microbiome Industry Opportunities and Challenges
2.4 Human Microbiome Industry Restraints
3 Global Growth Perspective
3.1 Global Human Microbiome Market Perspective (2019-2030)
3.2 Global Human Microbiome Growth Trends by Region
3.2.1 Global Human Microbiome Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Human Microbiome Market Size by Region (2019-2024)
3.2.3 Global Human Microbiome Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Human Microbiome Revenue by Players
4.1.1 Global Human Microbiome Revenue by Players (2019-2024)
4.1.2 Global Human Microbiome Revenue Market Share by Players (2019-2024)
4.1.3 Global Human Microbiome Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Human Microbiome Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Human Microbiome Key Players Headquarters & Area Served
4.4 Global Human Microbiome Players, Product Type & Application
4.5 Global Human Microbiome Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Human Microbiome Market CR5 and HHI
4.6.2 Global Top 5 and 10 Human Microbiome Players Market Share by Revenue in 2023
4.6.3 2023 Human Microbiome Tier 1, Tier 2, and Tier 3
5 Human Microbiome Market Size by Type
5.1 Global Human Microbiome Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Human Microbiome Revenue by Type (2019-2030)
5.3 Global Human Microbiome Revenue Market Share by Type (2019-2030)
6 Human Microbiome Market Size by Application
6.1 Global Human Microbiome Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Human Microbiome Revenue by Application (2019-2030)
6.3 Global Human Microbiome Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Vedanta
7.1.1 Vedanta Comapny Information
7.1.2 Vedanta Business Overview
7.1.3 Vedanta Human Microbiome Revenue and Gross Margin (2019-2024)
7.1.4 Vedanta Human Microbiome Product Portfolio
7.1.5 Vedanta Recent Developments
7.2 Seres Therapeutics
7.2.1 Seres Therapeutics Comapny Information
7.2.2 Seres Therapeutics Business Overview
7.2.3 Seres Therapeutics Human Microbiome Revenue and Gross Margin (2019-2024)
7.2.4 Seres Therapeutics Human Microbiome Product Portfolio
7.2.5 Seres Therapeutics Recent Developments
7.3 Second Genome
7.3.1 Second Genome Comapny Information
7.3.2 Second Genome Business Overview
7.3.3 Second Genome Human Microbiome Revenue and Gross Margin (2019-2024)
7.3.4 Second Genome Human Microbiome Product Portfolio
7.3.5 Second Genome Recent Developments
7.4 Rebiotix
7.4.1 Rebiotix Comapny Information
7.4.2 Rebiotix Business Overview
7.4.3 Rebiotix Human Microbiome Revenue and Gross Margin (2019-2024)
7.4.4 Rebiotix Human Microbiome Product Portfolio
7.4.5 Rebiotix Recent Developments
7.5 ActoGeniX
7.5.1 ActoGeniX Comapny Information
7.5.2 ActoGeniX Business Overview
7.5.3 ActoGeniX Human Microbiome Revenue and Gross Margin (2019-2024)
7.5.4 ActoGeniX Human Microbiome Product Portfolio
7.5.5 ActoGeniX Recent Developments
7.6 Enterome BioScience
7.6.1 Enterome BioScience Comapny Information
7.6.2 Enterome BioScience Business Overview
7.6.3 Enterome BioScience Human Microbiome Revenue and Gross Margin (2019-2024)
7.6.4 Enterome BioScience Human Microbiome Product Portfolio
7.6.5 Enterome BioScience Recent Developments
7.7 AvidBiotics
7.7.1 AvidBiotics Comapny Information
7.7.2 AvidBiotics Business Overview
7.7.3 AvidBiotics Human Microbiome Revenue and Gross Margin (2019-2024)
7.7.4 AvidBiotics Human Microbiome Product Portfolio
7.7.5 AvidBiotics Recent Developments
7.8 4D Pharma Research Ltd
7.8.1 4D Pharma Research Ltd Comapny Information
7.8.2 4D Pharma Research Ltd Business Overview
7.8.3 4D Pharma Research Ltd Human Microbiome Revenue and Gross Margin (2019-2024)
7.8.4 4D Pharma Research Ltd Human Microbiome Product Portfolio
7.8.5 4D Pharma Research Ltd Recent Developments
7.9 Enterologics
7.9.1 Enterologics Comapny Information
7.9.2 Enterologics Business Overview
7.9.3 Enterologics Human Microbiome Revenue and Gross Margin (2019-2024)
7.9.4 Enterologics Human Microbiome Product Portfolio
7.9.5 Enterologics Recent Developments
7.10 Metabogen
7.10.1 Metabogen Comapny Information
7.10.2 Metabogen Business Overview
7.10.3 Metabogen Human Microbiome Revenue and Gross Margin (2019-2024)
7.10.4 Metabogen Human Microbiome Product Portfolio
7.10.5 Metabogen Recent Developments
7.11 Metabiomics
7.11.1 Metabiomics Comapny Information
7.11.2 Metabiomics Business Overview
7.11.3 Metabiomics Human Microbiome Revenue and Gross Margin (2019-2024)
7.11.4 Metabiomics Human Microbiome Product Portfolio
7.11.5 Metabiomics Recent Developments
7.12 Ritter Pharmaceuticals
7.12.1 Ritter Pharmaceuticals Comapny Information
7.12.2 Ritter Pharmaceuticals Business Overview
7.12.3 Ritter Pharmaceuticals Human Microbiome Revenue and Gross Margin (2019-2024)
7.12.4 Ritter Pharmaceuticals Human Microbiome Product Portfolio
7.12.5 Ritter Pharmaceuticals Recent Developments
7.13 Osel
7.13.1 Osel Comapny Information
7.13.2 Osel Business Overview
7.13.3 Osel Human Microbiome Revenue and Gross Margin (2019-2024)
7.13.4 Osel Human Microbiome Product Portfolio
7.13.5 Osel Recent Developments
7.14 Symberix
7.14.1 Symberix Comapny Information
7.14.2 Symberix Business Overview
7.14.3 Symberix Human Microbiome Revenue and Gross Margin (2019-2024)
7.14.4 Symberix Human Microbiome Product Portfolio
7.14.5 Symberix Recent Developments
7.15 Miomics
7.15.1 Miomics Comapny Information
7.15.2 Miomics Business Overview
7.15.3 Miomics Human Microbiome Revenue and Gross Margin (2019-2024)
7.15.4 Miomics Human Microbiome Product Portfolio
7.15.5 Miomics Recent Developments
7.16 Symbiotix Biotherapies
7.16.1 Symbiotix Biotherapies Comapny Information
7.16.2 Symbiotix Biotherapies Business Overview
7.16.3 Symbiotix Biotherapies Human Microbiome Revenue and Gross Margin (2019-2024)
7.16.4 Symbiotix Biotherapies Human Microbiome Product Portfolio
7.16.5 Symbiotix Biotherapies Recent Developments
7.17 MicroBiome Therapeutics LLC
7.17.1 MicroBiome Therapeutics LLC Comapny Information
7.17.2 MicroBiome Therapeutics LLC Business Overview
7.17.3 MicroBiome Therapeutics LLC Human Microbiome Revenue and Gross Margin (2019-2024)
7.17.4 MicroBiome Therapeutics LLC Human Microbiome Product Portfolio
7.17.5 MicroBiome Therapeutics LLC Recent Developments
8 North America
8.1 North America Human Microbiome Revenue (2019-2030)
8.2 North America Human Microbiome Revenue by Type (2019-2030)
8.2.1 North America Human Microbiome Revenue by Type (2019-2024)
8.2.2 North America Human Microbiome Revenue by Type (2025-2030)
8.3 North America Human Microbiome Revenue Share by Type (2019-2030)
8.4 North America Human Microbiome Revenue by Application (2019-2030)
8.4.1 North America Human Microbiome Revenue by Application (2019-2024)
8.4.2 North America Human Microbiome Revenue by Application (2025-2030)
8.5 North America Human Microbiome Revenue Share by Application (2019-2030)
8.6 North America Human Microbiome Revenue by Country
8.6.1 North America Human Microbiome Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Human Microbiome Revenue by Country (2019-2024)
8.6.3 North America Human Microbiome Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 Europe
9.1 Europe Human Microbiome Revenue (2019-2030)
9.2 Europe Human Microbiome Revenue by Type (2019-2030)
9.2.1 Europe Human Microbiome Revenue by Type (2019-2024)
9.2.2 Europe Human Microbiome Revenue by Type (2025-2030)
9.3 Europe Human Microbiome Revenue Share by Type (2019-2030)
9.4 Europe Human Microbiome Revenue by Application (2019-2030)
9.4.1 Europe Human Microbiome Revenue by Application (2019-2024)
9.4.2 Europe Human Microbiome Revenue by Application (2025-2030)
9.5 Europe Human Microbiome Revenue Share by Application (2019-2030)
9.6 Europe Human Microbiome Revenue by Country
9.6.1 Europe Human Microbiome Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Human Microbiome Revenue by Country (2019-2024)
9.6.3 Europe Human Microbiome Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Human Microbiome Revenue (2019-2030)
10.2 China Human Microbiome Revenue by Type (2019-2030)
10.2.1 China Human Microbiome Revenue by Type (2019-2024)
10.2.2 China Human Microbiome Revenue by Type (2025-2030)
10.3 China Human Microbiome Revenue Share by Type (2019-2030)
10.4 China Human Microbiome Revenue by Application (2019-2030)
10.4.1 China Human Microbiome Revenue by Application (2019-2024)
10.4.2 China Human Microbiome Revenue by Application (2025-2030)
10.5 China Human Microbiome Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Human Microbiome Revenue (2019-2030)
11.2 Asia Human Microbiome Revenue by Type (2019-2030)
11.2.1 Asia Human Microbiome Revenue by Type (2019-2024)
11.2.2 Asia Human Microbiome Revenue by Type (2025-2030)
11.3 Asia Human Microbiome Revenue Share by Type (2019-2030)
11.4 Asia Human Microbiome Revenue by Application (2019-2030)
11.4.1 Asia Human Microbiome Revenue by Application (2019-2024)
11.4.2 Asia Human Microbiome Revenue by Application (2025-2030)
11.5 Asia Human Microbiome Revenue Share by Application (2019-2030)
11.6 Asia Human Microbiome Revenue by Country
11.6.1 Asia Human Microbiome Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Human Microbiome Revenue by Country (2019-2024)
11.6.3 Asia Human Microbiome Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Human Microbiome Revenue (2019-2030)
12.2 MEALA Human Microbiome Revenue by Type (2019-2030)
12.2.1 MEALA Human Microbiome Revenue by Type (2019-2024)
12.2.2 MEALA Human Microbiome Revenue by Type (2025-2030)
12.3 MEALA Human Microbiome Revenue Share by Type (2019-2030)
12.4 MEALA Human Microbiome Revenue by Application (2019-2030)
12.4.1 MEALA Human Microbiome Revenue by Application (2019-2024)
12.4.2 MEALA Human Microbiome Revenue by Application (2025-2030)
12.5 MEALA Human Microbiome Revenue Share by Application (2019-2030)
12.6 MEALA Human Microbiome Revenue by Country
12.6.1 MEALA Human Microbiome Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Human Microbiome Revenue by Country (2019-2024)
12.6.3 MEALA Human Microbiome Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings